Manufacturer of Controlled Substances; Notice of Registration, 17969-17970 [2011-7547]
Download as PDF
<![CDATA[
17969
Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices
(2010) in bulk active pharmaceutical
ingredient (API) form for distribution to
the company’s customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–7539 Filed 3–30–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated November 1, 2010,
and published in the Federal Register
on November 12, 2010, 75 FR 69464,
Cerilliant Corporation, 811 Paloma
Drive, Suite A, Round Rock, Texas
78665–2402, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
wwoods2 on DSK1DXX6B1PROD with NOTICES
Drug
Schedule
Cathinone (1235) ........................
Methcathinone (1237) .................
N-Ethylamphetamine (1475) .......
N,N-Dimethylamphetamine
(1480).
Aminorex (1585) .........................
4-Methylaminorex (cis isomer)
(1590).
Gamma-Hydroxybutyric acid
(2010).
Methaqualone (2565) .................
Alpha-ethyltryptamine (7249) .....
Lysergic acid diethylamide
(7315).
VerDate Mar<15>2010
11:23 Mar 31, 2011
I
I
I
I
I
I
I
I
I
I
Jkt 223001
Drug
Schedule
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .......................
Tetrahydrocannabinols (7370) ....
Mescaline (7381) ........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
5-Methoxy-3,4methylenedioxyamphetamine
(7401).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ..
Alpha-methyltryptamine (7432) ..
Bufotenine (7433) .......................
Diethyltryptamine (7434) ............
Dimethyltryptamine (7435) .........
Psilocybin (7437) ........................
Psilocyn (7438) ...........................
5-Methoxy-N,Ndiisopropyltyptamine (7439).
N-Benzylpiperazine (7493) .........
Acetyldihydrocodeine (9051) ......
Benzylmorphine (9052) ..............
Codeine-N-oxide (9053) .............
Dihydromorphine (9145) .............
Heroin (9200) ..............................
Hydromorphinol (9301) ...............
Methyldihydromorphine (9304) ...
Morphine-N-oxide (9307) ............
Normorphine (9313) ...................
Pholcodine (9314) ......................
Acetylmethadol (9601) ................
Allylprodine (9602) ......................
Alphacetylmethadol except levoalphacetylmethadol (9603).
Alphameprodine (9604) ..............
Alphamethadol (9605) ................
Betacetylmethadol (9607) ...........
Betameprodine (9608) ................
Betamethadol (9609) ..................
Betaprodine (9611) .....................
Hydroxypethidine (9627) ............
Noracymethadol (9633) ..............
Norlevorphanol (9634) ................
Normethadone (9635) ................
Trimeperidine (9646) ..................
Phenomorphan (9647) ................
1–Methyl-4-phenyl-4propionoxypiperidine (9661).
Tilidine (9750) .............................
Para-Fluorofentanyl (9812) .........
3–Methylfentanyl (9813) .............
Alpha-Methylfentanyl (9814) .......
PO 00000
Frm 00153
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Drug
Acetyl-alpha-methylfentanyl
(9815).
Beta-hydroxyfentanyl (9830) ......
Beta-hydroxy-3-methylfentanyl
(9831).
Alpha-Methylthiofentanyl (9832)
3–Methylthiofentanyl (9833) .......
Thiofentanyl (9835) .....................
Amphetamine (1100) ..................
Methamphetamine (1105) ..........
Lisdexamfetamine (1205) ...........
Phenmetrazine (1631) ................
Methylphenidate (1724) ..............
Amobarbital (2125) .....................
Pentobarbital (2270) ...................
Secobarbital (2315) ....................
Glutethimide (2550) ....................
Nabilone (7379) ..........................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ..................
1Piperidinocyclohexanecarbonitrile (8603).
Alphaprodine (9010) ...................
Cocaine (9041) ...........................
Codeine (9050) ...........................
Dihydrocodeine (9120) ...............
Oxycodone (9143) ......................
Hydromorphone (9150) ..............
Diphenoxylate (9170) .................
Benzoylecgonine (9180) .............
Ethylmorphine (9190) .................
Hydrocodone (9193) ...................
Levomethorphan (9210) .............
Levorphanol (9220) ....................
Isomethadone (9226) .................
Meperidine (9230) ......................
Meperidine intermediate-A
(9232).
Meperidine intermediate-B
(9233).
Meperidine intermediate-C
(9234).
Methadone (9250) ......................
Methadone intermediate (9254)
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) .........................
Thebaine (9333) .........................
Levo-alphacetylmethadol (9648)
Oxymorphone (9652) ..................
Noroxymorphone (9668) .............
Racemethorphan (9732) .............
Alfentanil (9737) .........................
Sufentanil (9740) ........................
Tapentadol (9780) ......................
Fentanyl (9801) ..........................
Schedule
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cerilliant Corporation to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Cerilliant Corporation to
E:\FR\FM\31MR1.SGM
31MR1
17970
Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
eligibility requirements, review and
selection procedures and other program
requirements governing this solicitation.
DATES: The closing date for receipt of
applications is April 29, 2011.
FOR FURTHER INFORMATION CONTACT:
Latifa Jeter, 200 Constitution Avenue,
NW., Room N4716, Washington, DC
20210; Telephone: 202–693–3553.
site https://www.nsf.gov/nsb for
additional information and schedule
updates (time, place, subject matter or
status of meeting) may be found at
https://www.nsf.gov/nsb/notices/. Point
of contact for this meeting is: Matthew
B. Wilson, National Science Board
Office, 4201 Wilson Blvd., Arlington,
VA 22230. Telephone: (703) 292–7000.
Signed at Washington, DC, this 25th day of
March, 2011.
Eric D. Luetkenhaus,
Grant Officer, Employment and Training
Administration.
Daniel A. Lauretano,
Counsel to the National Science Board.
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–7556 Filed 3–30–11; 8:45 am]
Board Meeting: April 27, 2011—
Amherst, New York; the U.S. Nuclear
Waste Technical Review Board Will
Meet To Discuss the West Valley
Demonstration Project
National Science Board; Sunshine Act
Meetings; Notice
DEPARTMENT OF LABOR
Employment and Training
Administration
Notice of Funding Opportunity and
Solicitation for Grant Applications
(SGA) for the Young Parents
Demonstration
Employment and Training
Administration, Labor.
ACTION: Notice of Solicitation for Grant
Applications (SGA).
AGENCY:
wwoods2 on DSK1DXX6B1PROD with NOTICES
NUCLEAR WASTE TECHNICAL
REVIEW BOARD
NATIONAL SCIENCE FOUNDATION
BILLING CODE 4410–09–P
Funding Opportunity Number: SGA/
DFA PY–10–12
SUMMARY: The Employment and
Training Administration (ETA), U.S.
Department of Labor announces the
availability of approximately $5.5
million authorized by the Consolidated
Appropriations Act of 2010 to support
applicants in providing intensive
mentoring services to low-income young
parents (both mothers and fathers, and
expectant parents ages 16 to 24)
participating in workforce development
programs. Activities under this SGA are
authorized under Section 171(b) of the
Workforce Investment Act, which
allows for demonstration and pilot
projects for the purpose of developing
and implementing techniques and
approaches, and demonstrating the
effectiveness of specialized methods, in
addressing employment and training
needs.
The complete SGA and any
subsequent SGA amendments, in
connection with the Consolidated
Appropriations Act of 2010 is described
in further detail on ETA’s Web site at
https://www.doleta.gov/grants or on
https://www.grants.gov. The Web sites
provide application information,
11:23 Mar 31, 2011
Jkt 223001
BILLING CODE 7555–01–P
BILLING CODE 4510–FN–P
[FR Doc. 2011–7547 Filed 3–30–11; 8:45 am]
VerDate Mar<15>2010
[FR Doc. 2011–7694 Filed 3–29–11; 11:15 am]
The National Science Board’s
Committee on Education and Human
Resources (CEH), pursuant to NSF
regulations (45 CFR part 614), the
National Science Foundation Act, as
amended (42 U.S.C. 1862n–5), and the
Government in the Sunshine Act (5
U.S.C. 552b), hereby gives notice in
regard to the scheduling of a
teleconference for the transaction of
National Science Board business and
other matters specified, as follows:
DATE AND TIME: April 7, 2011, 10:30
a.m.–12 p.m. EST.
SUBJECT MATTER: Discussion of the
Committee on Education and Human
Resources (CEH) STEM education
prospective ‘‘action items’’ (to be
developed at the teleconference) and
discussion of the May 10–11, 2011 CEH
meeting agenda.
STATUS: Open.
LOCATION: This meeting will be held by
teleconference at the National Science
Board Office, National Science
Foundation, 4201 Wilson Blvd.,
Arlington, VA 22230. A room will be
available for the public to listen-in to
this meeting held by teleconference at
Stafford Place I, National Science
Foundation, 4201 Wilson Blvd.,
Arlington, VA 22230. All visitors must
contact the Board Office [call 703–292–
7000 or send an e-mail message to
nationalsciencebrd@nsf.gov] at least 24
hours prior to the teleconference for the
room number and provide name and
organizational affiliation. All visitors
must report to the NSF visitor desk
located in the lobby at the 9th and N.
Stuart Streets entrance on the day of the
teleconference to receive a visitor’s
badge.
UPDATES AND POINT OF CONTACT: Please
refer to the National Science Board Web
PO 00000
Frm 00154
Fmt 4703
Sfmt 4703
Pursuant to its authority under
section 5051 of Public Law 100–203,
Nuclear Waste Policy Amendments Act
of 1987, the U.S. Nuclear Waste
Technical Review Board will hold a
public meeting in Amherst, New York,
on Wednesday, April 27, 2011, to
discuss the West Valley Demonstration
Project (WVDP). Currently planned are
presentations on the WVDP by
representatives of the New York State
Energy Research and Development
Authority and the U.S. Department of
Energy’s (DOE) Office of Environmental
Management. Other issues expected to
be discussed include previous
reprocessing and vitrification activities
at the WVDP; long-term onsite storage of
vitrified high-level radioactive waste
(HLW); determination of waste
classification of the melter from the
vitrification facility; and the final
Environmental Impact Statement and
Record of Decision on decommissioning
and/or long-term stewardship at the
WVDP. Also planned are presentations
and a panel discussion on the 2008–9
study on Quantitative Risk Assessment
of the State Licensed Radioactive Waste
Disposal Area.
The meeting will be held at the
Buffalo Marriott Niagara; 1340
Millersport Highway; Amherst, New
York 14221; (tel) 716–689–6900; (fax)
716–689–0483. A block of rooms has
been reserved at the hotel for meeting
attendees. To ensure receiving the
meeting rate, room reservations must be
made by April 8, 2011.
Reservations can be made online at
https://www.buffaloniagaramarriott.com
using the following procedure: In the
‘‘Rates & Availability’’ box, enter the
reservation dates; click ‘‘Special Rates &
E:\FR\FM\31MR1.SGM
31MR1
]]>Agencies
[Federal Register Volume 76, Number 62 (Thursday, March 31, 2011)]
[Notices]
[Pages 17969-17970]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-7547]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated November 1, 2010, and published in the Federal
Register on November 12, 2010, 75 FR 69464, Cerilliant Corporation, 811
Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application
by renewal to the Drug Enforcement Administration (DEA) to be
registered as a bulk manufacturer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
Aminorex (1585)............................ I
4-Methylaminorex (cis isomer) (1590)....... I
Gamma-Hydroxybutyric acid (2010)........... I
Methaqualone (2565)........................ I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
3,4,5-Trimethoxyamphetamine (7390)......... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
3,4-Methylenedioxyamphetamine (7400)....... I
5-Methoxy-3,4-methylenedioxyamphetamine I
(7401).
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (7405)... I
4-Methoxyamphetamine (7411)................ I
Alpha-methyltryptamine (7432).............. I
Bufotenine (7433).......................... I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
5-Methoxy-N,N-diisopropyltyptamine (7439).. I
N-Benzylpiperazine (7493).................. I
Acetyldihydrocodeine (9051)................ I
Benzylmorphine (9052)...................... I
Codeine-N-oxide (9053)..................... I
Dihydromorphine (9145)..................... I
Heroin (9200).............................. I
Hydromorphinol (9301)...................... I
Methyldihydromorphine (9304)............... I
Morphine-N-oxide (9307).................... I
Normorphine (9313)......................... I
Pholcodine (9314).......................... I
Acetylmethadol (9601)...................... I
Allylprodine (9602)........................ I
Alphacetylmethadol except levo- I
alphacetylmethadol (9603).
Alphameprodine (9604)...................... I
Alphamethadol (9605)....................... I
Betacetylmethadol (9607)................... I
Betameprodine (9608)....................... I
Betamethadol (9609)........................ I
Betaprodine (9611)......................... I
Hydroxypethidine (9627).................... I
Noracymethadol (9633)...................... I
Norlevorphanol (9634)...................... I
Normethadone (9635)........................ I
Trimeperidine (9646)....................... I
Phenomorphan (9647)........................ I
1-Methyl-4-phenyl-4-propionoxypiperidine I
(9661).
Tilidine (9750)............................ I
Para-Fluorofentanyl (9812)................. I
3-Methylfentanyl (9813).................... I
Alpha-Methylfentanyl (9814)................ I
Acetyl-alpha-methylfentanyl (9815)......... I
Beta-hydroxyfentanyl (9830)................ I
Beta-hydroxy-3-methylfentanyl (9831)....... I
Alpha-Methylthiofentanyl (9832)............ I
3-Methylthiofentanyl (9833)................ I
Thiofentanyl (9835)........................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Lisdexamfetamine (1205).................... II
Phenmetrazine (1631)....................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Glutethimide (2550)........................ II
Nabilone (7379)............................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
1-Piperidinocyclohexanecarbonitrile (8603). II
Alphaprodine (9010)........................ II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Diphenoxylate (9170)....................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Hydrocodone (9193)......................... II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Isomethadone (9226)........................ II
Meperidine (9230).......................... II
Meperidine intermediate-A (9232)........... II
Meperidine intermediate-B (9233)........... II
Meperidine intermediate-C (9234)........... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Racemethorphan (9732)...................... II
Alfentanil (9737).......................... II
Sufentanil (9740).......................... II
Tapentadol (9780).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances to make reference standards which will be
distributed to their customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Cerilliant Corporation to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Cerilliant Corporation to
[[Page 17970]]
ensure that the company's registration is consistent with the public
interest. The investigation has included inspection and testing of the
company's physical security systems, verification of the company's
compliance with state and local laws, and a review of the company's
background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in
accordance with 21 CFR 1301.33, the above named company is granted
registration as a bulk manufacturer of the basic classes of controlled
substances listed.
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-7547 Filed 3-30-11; 8:45 am]
BILLING CODE 4410-09-P
